As I said; you are clearly bothered by contact details in signatures.
Why?
Will removal of contact details make NOR a better stock?
Back on topic; the Q today was woeful and laughable. Repeated sentences; $50k in the bank; continuation of the same carrot dangling; a declining business which really should be taken behind the shed and put out of its misery.
Avicena looks promising though... opportunistic of course. A pivot from mineral assays to Covid. Wow. How?
All imo
Ann: Quarterly Activities and Appendix 4C Cashflow Report, page-56
-
- There are more pages in this discussion • 396 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
